On the other hand, our data highlight IL-9, which is overexpressed in CLL patients with aggressive disease presentation [17, 30, 32], as a key pro-tumoral cytokine that shapes the TME not only to promote leukemic cell accumulation and survival [17], but also to help them evade elimination by CTLs. Here, IL9 is linked to B-cell chronic lymphocytic leukemia.